The impact of the conditioning intensity and TBI on acute GVHD (aGVHD) is still a matter of debate. We analyzed 6848 adult recipients who received allogeneic hematopoietic cell transplants (HCT) between 2006 and 2011 in Japan. The subjects were divided into groups who had received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), either with or without TBI. There was a significant difference in the incidence of aGVHD 2-4 among the different conditioning types: 39% in TBI-MAC, 35% in TBI-RIC and 32% in both no-TBI MAC and no-TBI-RIC (P o 0.001). In a multivariate analysis, TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD 2-4 (hazard ratio (HR) 1.33, P o 0.01), whereas TBI-RIC was associated with an increased risk of GVHD 3-4 (HR 1.36, P = 0.048). TBI-MAC and TBI-RIC were significantly associated with skin and gastrointestinal aGVHD. Subgroup analyses demonstrated that not only TBI-MAC, but also TBI-RIC, was significantly associated with aGVHD 2-4 in older patients. Furthermore, high-dose TBI only had an adverse impact on aGVHD 2-4 in HLA-matched HCT. Impacts of intensity and TBI on aGVHD differ by patient backgrounds, and this difference should be considered to establish a risk-adapted strategy for the prevention of aGVHD.
INTRODUCTION
Since allogeneic hematopoietic cell transplantation (HCT) was introduced about 50 years ago, the procedure has spread widely because of its potential to cure hematological malignancies. 1 Recent major progress in HCT has been due to the development of stem cell sources such as PBSC or unrelated cord blood (UCB), alternative donors, novel strategies for immunosuppression and reduced-intensity conditioning (RIC). However, among many other possible complications, HCT patients also have to overcome acute GVHD (aGVHD) in the early phase. The exact pathophysiology of aGVHD is still unclear, but interactions among donor T cells, host APCs and host tissues are considered to have a role. 2, 3 Several risk factors for aGVHD have been identified, including age; donor type, such as unrelated, HLA-mismatched, gendermismatched or ABO-mismatched donors; donor source, such as mobilized peripheral blood, BM or cord blood; conditioning intensity; and GVHD prophylaxis. [3] [4] [5] [6] Among these, the impact of the conditioning intensity and TBI on aGVHD is still a matter of debate. 4, 5, [7] [8] [9] [10] [11] To the best of our knowledge, the Center for International and Blood Marrow Transplant Research reported the largest study, which included over 5000 recipients who received a transplant between 1999 and 2005 to identify the risk factors for aGVHD. 5 They analyzed the impact of the type of conditioning in sibling donors and unrelated donors, and concluded that the conditioning intensity, TBI and graft source have a combined effect on the risk of aGVHD. One of the difficulties in evaluating the impact of the conditioning intensity on the clinical outcome is that the selection of RIC or myeloablative conditioning (MAC) is generally determined based on patient/donor characteristics, such as age, HLA mismatch and donor type. In addition, TBI might be used more frequently for younger recipients or in unrelated/HLAmismatch HCT. Therefore, the impact of the conditioning intensity and TBI on the clinical outcome may vary according to the patient background. If we consider the variety of donor types that are now available, including HLA-mismatched donors and UCB, further subgroup analyses are warranted in studies of recent cohorts.
PATIENTS AND METHODS

Patient selection
This study included adult and adolescent recipients (415-year old) with AML, ALL, CML or myelodysplastic syndrome who received their first 12 For recipients to be considered eligible, information on age, sex, HLA, conditioning regimen, the presence of aGVHD and survival status at the end of follow-up were required. We excluded patients who received low-dose TBI in addition to chemo-based MAC, those who received GVHD prophylaxis other than CsA/tacrolimus (Tac) with MTX and those who received antithymocyte globulin or Campath. Finally, 6848 recipients were analyzed. The median duration of follow-up in survivors was 2.5 years. This retrospective analysis was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board at Saitama Medical Center, Jichi Medical University.
Definitions of categories
Conditioning regimens were classified as MAC or RIC based on the report by Giralt et al. 13 Briefly, conditioning regimens that included TBI48 Gy, Impact of conditioning intensity and TBI on aGVHD H Nakasone et al melphalan ⩾ 140 mg/m 2 or oral BU ⩾ 9 mg/kg (i.v. BU ⩾ 7.2 mg/kg) were classified as MAC. Other regimens were classified as RIC. The conditioning types were then divided into four groups: TBI (48 Gy)-MAC, no-TBI-MAC, TBI (⩽8 Gy)-RIC and no-TBI RIC. The diagnosis and severity of aGVHD were reported based on clinical grading scores. 14, 15 Standard-risk diseases were defined as follows: acute leukemia in the first and second CR, CML in the first and second chronic phase and myelodysplastic syndrome other than refractory anemia with excess blasts. Other diseases were classified as high risk. As PBSC from unrelated donors was rarely available in Japan during the evaluation period, the donor types of HCT were categorized into seven groups: HLA-matched related BM, HLAmatched related PBSC, HLA-mismatched related BM, HLA-mismatched related PBSC, HLA-matched unrelated BM, HLA-mismatched unrelated BM (MMUD-BM), and UCB. HLA-match was defined as a 6/6 serological match of HLA-A, -B and -DR in related donors and UCB, and a 6/6 allelic match of HLA-A, B and -DRB1 in unrelated BM.
Statistical analysis
Categorical variables were compared using the χ 2 -test. The cumulative incidences of grade II-IV (aGVHD 2-4) and grade III-IV aGVHD (aGVHD 3-4) were estimated and compared by Gray's method, where death without these events was considered as a competing risk. These probabilities were estimated with a 95% confidence interval (CI). In a multivariate analysis, the Fine-Gray method was used to evaluate the cumulative incidences of aGVHD. In the multivariate analysis, the hazard ratios (HRs) of conditioning types were obtained after adjusting for the following variables: gender, age, disease, disease risk, CMV serostatus, performance status, donor type, ABO-mismatch, sex-mismatch and GVHD prophylaxis. The impact of the conditioning type was also compared in subgroups of MAC and RIC stratified according to the recipient age divided by a median ( o45 or ⩾ 45) or donor type (MRD, MMRD, MUD, MMUD and UCB). We did not assess the impact of the conditioning type on aGVHD 3-4 in the RIC with UCB group, as only 1 patient experienced aGVHD 3-4 in no-TBI-RIC with UCB. The associations between the incidences of aGVHD in the skin, gut and liver and the conditioning type were also assessed, and HR was shown after being adjusted for the same variables as above. Statistical significance was defined as a two-tailed P-value of o0.05. All data management and statistical calculations were performed using Stata version 12.0 (Stata Corp., College Station, TX, USA) and EZR, which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0, Vienna, Austria) (Saitama Medical Centre, Jichi Medical University at http://www. jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html). 16 
RESULTS
Patient characteristics
Of the 6848 recipients, 3879 received TBI-MAC (57%), 1234 received no-TBI MAC (18%), 1126 received TBI-RIC (16%) and 609 received no-TBI RIC (9%). Their patient characteristics were quite different (Table 1) . TBI-MAC and no-TBI MAC were frequently used in younger recipients, whereas TBI-RIC and no-TBI RIC were used in older patients. ALL accounted for 36% of the TBI-MAC patients and this proportion was higher than those in the other conditioning types (o 15% in each group). TBI-MAC included more standardrisk diseases (64%). Regarding the donor type, alternative donors other than MRD accounted for 88% in TBI-RIC, whereas the other conditioning groups included more MRD (28% in TBI-MAC, 36% in no-TBI MAC and 45% in no-TBI RIC).
Grade II-IV aGVHD Of the 6848 recipients, 2508 experienced aGVHD 2-4, with a cumulative incidence of 36% (95% CI: 35-38%) at 100 days post HCT. The cumulative incidences of aGVHD 2-4 in TBI-containing conditioning types (39% (95%CI: 38-41%) in TBI-MAC and 35% (95% CI: 32-38%) in TBI-RIC) were higher than those in no-TBI regimens (32% (95%CI: 29-34%) in no-TBI MAC and 32% (95%CI: 29-36%) in no-TBI RIC, P o0.0001, Figure 1a) . A multivariate analysis of the overall cohort revealed that TBI-MAC was significantly associated with an increased risk for aGVHD 2-4 (HR 1.33, P = 0.0012, Table 2 ). Focusing only on high risk, standard risk and myeloid malignancies, TBI-MAC was consistently associated with an increased risk of aGVHD 2-4.
If we focus on the subgroups stratified according to age (⩾45 or o45 years), TBI-containing conditioning was significantly associated with an increased risk of aGVHD 2-4 for both MAC (HR 1.44, P o0.001) and RIC (HR 1.30, P = 0.021) among older patients (⩾45 years, Figure 2a) , whereas among younger patients (o45 years), the adverse effect of TBI on aGVHD 2-4 was observed only in MAC (HR 1.23, P = 0.036) and not in RIC (Figure 2b ).
If we focus on the MAC group stratified according to the donor type (MRD, MMRD, MUD, MMUD and UCB), TBI-MAC was significantly associated with an increased risk of aGVHD 2-4 in MRD (HR 1.38, P = 0.0073) and MUD (HR 1.51, P o0.001), but not in MMRD, MMUD or UCB (Figure 3a) . In the RIC group, TBI-RIC was significantly associated with an increased risk of aGVHD 2-4 (HR 1.60, P = 0.011) in MRD, but not in any other alternative donor groups (Figure 3b ).
Grade III-IV aGVHD Grade III-IV aGVHD was observed in 770 recipients, with a cumulative incidence of 11% (95% CI: 10-12%) at 100 days post HCT. There was no significant difference among the conditioning types (11% (95% CI: 10-12%) in TBI-MAC, 11% (95% CI: 10-13%) in no-TBI MAC, 13% (95% CI: 11-15%) in TBI-RIC, and 11% (95% CI: Impact of conditioning intensity and TBI on aGVHD H Nakasone et al 8-13%) in no-TBI RIC, P = 0.15, Figure 1b) . In a multivariate analysis of the overall cohort, TBI-RIC was associated with an increased risk of GVHD 3-4 (HR 1.36, P = 0.048) compared with no-TBI RIC (Table 2 ). In the MAC group, TBI-MAC was not associated with an increased risk of aGVHD 3-4 in the subgroups stratified according to age or donor type (Figures 2 and 3a) . In the RIC group, TBI-RIC was associated with an increased risk of aGVHD 3-4 (HR 1.64, P = 0.0087) only in older patients (⩾45 years) (Figure 2a ). There was no difference between TBI and no-TBI RIC in subgroups stratified according to the donor type (Figure 3b ).
Target organs of aGVHD Among the 3921 patients who experienced any grade of aGVHD, the skin, liver and gut were involved in 6%, the skin and gut in 21%, the skin and liver in 3%, the liver and gut in 1%, only the skin in 61%, only the gut in 7% and only the liver in 1% (Figure 4) . Conditioning types that contained TBI were significantly associated with aGVHD of the skin (HR 1.40, P o 0.0001 in TBI-MAC; HR 1.17, P = 0.044 in TBI-RIC) and gut (HR 1.32, P = 0.025 in TBI-MAC; HR 1.37, P = 0.013 in TBI-RIC) ( Table 3) . On the other hand, none of the conditioning types was associated with aGVHD of the liver (Table 3 ).
Survival
Of the 6848 patients, 3084 died during the follow-up period and 1383 deaths were due to nonrelapse complications. Their nonrelapse mortality and OS at 2.5 years post HCT were 21% (95% CI: 20-22%) and 53% (95% CI: 52-55%), respectively. Multivariate analyses of the overall cohort showed that none of the conditioning types remained significant in association with nonrelapse mortality or OS.
DISCUSSION
On the basis of the Japan Society for Hematopoietic Cell Transplantation registry data of 6848 patients, this study revealed that TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD 2-4. TBI-MAC and -RIC were significant risk factors for skin and gastrointestinal GVHD. Subgroup analyses revealed that TBI had a prominent adverse effect on aGVHD 2-4 in older patients and HLA-matched donors, but not in HLA-mismatched donors.
The pathophysiology of aGVHD is generally considered to be the attack by infused donor lymphocytes, which are stimulated by damage to host tissue in addition to the foreign environment. 2, 3 Tissue damage due to conditioning of HCT is thought to be the first step in the activation of host APCs and initiates inflammatory Abbreviations: aGVHD = acute GVHD; CI = confidence interval; HR = hazard ratio; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; MMRD = HLA-mismatched related donor; MMUD = HLA-mismatched unrelated donor; MRD = HLA-matched related donor; MUD = HLA-matched unrelated donor; PB = peripheral blood; PS = performance status; RIC = reduced-intensity conditioning; Tac = tacrolimus; UCB = unrelated cord blood.
Impact of conditioning intensity and TBI on aGVHD H Nakasone et al conditions through cytokine production. 2, 3 In this regard, the use of RIC is expected to reduce the incidence and severity of GVHD by minimizing host tissue damage and consequently preventing the excess production of inflammatory cytokines. However, the actual impact of RIC on aGVHD seems to be controversial, as observed in previous studies. [8] [9] [10] 17, 18 RIC, which consists of TBI (2 Gy) with or without fludarabine was reported to reduce the incidence of severe aGVHD compared with that with MAC. 8 On the other hand, in patients 450 years old, fludarabine-based RIC was reported to show aGVHD 2-4 at an incidence comparable to that with MAC. 9 Furthermore, in the UCB setting, aGVHD 2-4 was observed more frequently in RIC patients than in MAC patients. 18 These different outcomes may be owing to differences in the backgrounds of patients and the institutional policies for choosing between conditioning and related GVHD prophylaxis. In the early 2000s when RIC was developed, calcineurin inhibitor alone was often used and rapidly tapered in an effort to induce GVL effects intentionally. 19 In this study, we exclusively analyzed patients who received CsA/Tac with MTX.
There was no difference between no-TBI MAC and no-TBI RIC with respect to aGVHD incidence, severity and involved target organs. This absence of difference suggests that intensity of chemo-based conditioning would not contribute to aGVHD development On the other hand, TBI-MAC was associated with an increased risk of aGVHD 2-4 ( Table 2 ), suggesting that TBI is a significant risk factor for aGVHD, as has been suggested previously. 4, 10 A myeloablative dose of TBI is a risk factor for mucositis and gastroenteritis after HCT, which have important roles in accelerating GVHD. [20] [21] [22] Surprisingly, a lower dose of TBI was also associated with gastrointestinal GVHD (Table 3) .
Therefore, we performed subgroup analyses that focused on the impact of TBI in both RIC and MAC, and found that the adverse Figure 3 . Impact of TBI in myeloablative and reduced-intensity conditioning stratified according to donor type. aGVHD, acute GVHD; HR, hazard ratio; CI, confidence interval; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning. HR was shown after adjusting for gender, age, disease, disease risk, CMV serostatus, performance status, donor type, ABO-mismatch, sex-mismatch and GVHD prophylaxis.
effect of TBI on aGVHD depended on patient age and donor type. In older patients (⩾45 years), the use of TBI was associated with an increased risk of aGVHD 2-4 in both the MAC and RIC groups. On the other hand, in younger patients ( o45 years), low-dose TBI was not associated with aGVHD in the RIC group, although highdose TBI was associated with an increased risk of GVHD, as in older patients. Thus, older patients are more sensitive to TBI, which contributes to the increase in aGVHD. Further subgroup analyses also demonstrated that the adverse effect of TBI on aGVHD was limited to HLA-matched HCT (MRD and MUD) in the MAC group. TBI did not have a synergistic effect on aGVHD with HLA mismatch. To the best of our knowledge, this study is the first to demonstrate that the type of conditioning differentially affects the transplant outcome according to the HLAmatching status.
This study has limitations in addition to its retrospective nature. First, the selection of the conditioning intensity and TBI is usually based on several factors, including age, disease, disease risk and donor type. Thus, it is natural that the patient characteristics would vary among the different conditioning types. In addition, TBI technique is reported as an extremely heterogeneous modality. 23 Therefore, the heterogeneity of their backgrounds and TBI itself should be taken into consideration when we interpret these results. Second, the large cohort could permit us to address their detail, but many subgroup analyses were performed. Careful interpretation might be required for the significant difference between P-value of 0.01 and 0.05 in subgroup analyses, although our final conclusion did not change.
In summary, TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD compared with no-TBI RIC. Subgroup analyses suggested that the adverse impact of TBI on aGVHD varied according to age and donor type. This difference in the impact of the conditioning type on aGVHD according to the patient background should be considered for future clinical investigations to establish a risk-adapted strategy for the prevention of aGVHD.
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